Key facts
- Approxima’s last known valuation is $4.8M (Feb 2023).
- It has raised $19.3M; the latest was Later Stage VC ($10.0M) in Mar 2026.
- Notable investors include Club degli investitori, Panakes Partners, Aegis Capital (Poland), Barbara Taddei, Bioindustry Park Silvano Fumero — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Approxima
- ·The full record, as it builds
Funding rounds
No funding rounds for Approxima are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Approxima
Developer of a novel treatment technology designed for patients with tricuspid valve regurgitation. The company's minimally invasive tricuspid valve repair system allows the reshaping of the right ventricle, counteracting the right heart dilation to treat patients with tricuspid valve regurgitation, enabling medical professionals to implant the device in the heart of a patient via a minimally invasive procedure guided by medical imaging under beating heart conditions.
- Sector
- Healthcare
- HQ
- Seregno, Italy
- Founded
- 2020
- Employees
- 6
- Website
- approximamedical.com/
- Ownership
- Privately Held (backing)
Approxima doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Approxima shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Approxima in its N-PORT filings yet. We sweep new filings monthly.